Effects of Curcumin Supplementation on Lipid Profile and Inflammatory Markers of Patients With Type 2 Diabetes

National Nutrition and Food Technology Institute

Status and phase: Unknown; Phase 3; Phase 2

Conditions: Non Insulin Dependent Diabetes

Treatments: Dietary Supplement: curcumin; Dietary Supplement: Placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT02529969

615

Details and patient eligibility

About

Diabetes mellitus is the most common endocrine disorder, causes many complications such as micro- and macro-vascular diseases. Various kinds of antidiabetic drugs have been developed, but most of them have side effects. Recently, the use of natural plant products has gained more attention among scientists in order to prevent diabetic vascular complications. Curcumin is a natural yellow product derived from the turmeric rhizome which has shown to be non-toxic and exhibits various bio¬logical activities such as anti-oxidant, anti-inflammatory, anti-carcinogenic, and anti-diabetic effects. Curcumin is effective in reducing glycemic index and hyperlipidemia in rodent models and is relatively inexpensive and safe. Most of the studies conducted on animal model, and just a few of them are on human model. The present study was planned to evaluate the effects of curcumin supplementation on serum levels of lipid profile and inflammatory markers in patients with type 2 diabetes

Enrollment: 50 estimated patients

Sex: All

Ages: 40 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Tendency to participate
2. Age range of 40-65
3. Suffering from diabetes type 2 ( between 1 to 10 yeares)
4. BMI 18/5-30
5. Patients with diabetes who administer oral hypoglycemic agents and do not use

Exclusion criteria

1. patients with liver diseases
2. patients with kidney diseases
3. patients with inflammatory diseases
4. patients with liver diseases
5. Administering herbal agents
6. Administering multivitamins and minerals in past 3 months

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

50 participants in 2 patient groups, including a placebo group

intervention

Active Comparator group

Description:

500 mg curcumin capsule

Treatment:

Dietary Supplement: curcumin

placebo

Placebo Comparator group

Description:

500 mg placebo

Treatment:

Dietary Supplement: Placebo